Author:
Wang Shuai,Wang Qin,Jin Lirong,Dong Jihong,Ding Jianyong
Reference11 articles.
1. ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial;Howard;Lancet Neurol.,2021
2. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study;Bril;Eur. J. Neurol.,2023
3. “Plasma exchange in a bottle”: an overview of efgartigimod for apheresis practitioners;Tran;J. Clin. Apher.,2022
4. The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines;Sohrabi;Int. J. Surg.,2023
5. Modified subxiphoid thoracoscopic thymectomy for locally invasive thymoma;Jiang;Ann. Thorac. Surg.,2021